SOLENO THERAPEUT. DL-001
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia… Read more
Market Cap & Net Worth: SOLENO THERAPEUT. DL-001 (6XC)
SOLENO THERAPEUT. DL-001 (F:6XC) has a market capitalization of $1.58 Billion (€1.54 Billion) as of March 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #5698 globally and #599 in its home market, demonstrating a -13.55% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying SOLENO THERAPEUT. DL-001's stock price €28.70 by its total outstanding shares 53710025 (53.71 Million).
SOLENO THERAPEUT. DL-001 Market Cap History: 2019 to 2026
SOLENO THERAPEUT. DL-001's market capitalization history from 2019 to 2026. Data shows growth from $130.11 Million to $1.58 Billion (51.83% CAGR).
SOLENO THERAPEUT. DL-001 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how SOLENO THERAPEUT. DL-001's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 6XC by Market Capitalization
Companies near SOLENO THERAPEUT. DL-001 in the global market cap rankings as of March 19, 2026.
Key companies related to SOLENO THERAPEUT. DL-001 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
SOLENO THERAPEUT. DL-001 Historical Marketcap From 2019 to 2026
Between 2019 and today, SOLENO THERAPEUT. DL-001's market cap moved from $130.11 Million to $ 1.58 Billion, with a yearly change of 51.83%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €1.58 Billion | -27.19% |
| 2025 | €2.17 Billion | -5.96% |
| 2024 | €2.31 Billion | +101.54% |
| 2023 | €1.15 Billion | +1068.54% |
| 2022 | €98.13 Million | +358.76% |
| 2021 | €21.39 Million | -74.13% |
| 2020 | €82.70 Million | -36.44% |
| 2019 | €130.11 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of SOLENO THERAPEUT. DL-001 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.58 Billion USD |
| MoneyControl | $1.58 Billion USD |
| MarketWatch | $1.58 Billion USD |
| marketcap.company | $1.58 Billion USD |
| Reuters | $1.58 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.